Evaluation of liposome toll-like receptor ligand complexes for non-specific mucosal immunoprotection from feline herpesvirus-1 infection.
immunity
immunotherapy
innate
toll-like
Journal
Journal of veterinary internal medicine
ISSN: 1939-1676
Titre abrégé: J Vet Intern Med
Pays: United States
ID NLM: 8708660
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
12
02
2018
accepted:
11
01
2019
pubmed:
9
3
2019
medline:
11
5
2019
entrez:
9
3
2019
Statut:
ppublish
Résumé
Feline herpesvirus-1 (FHV-1) infection can result in serious morbidity and mortality, especially in kittens. Immunotherapy using liposome-toll-like receptor (TLR) ligand complexes (LTC) has been shown to activate innate immune responses. To determine in kittens whether mucosal administration of LTC before FHV-1 inoculation would decrease severity of clinical signs and decrease quantities of FHV-1 DNA in materials collected on oropharyngeal swabs. Nineteen, 14-week-old, purpose-bred kittens. Pilot clinical trial with 2 groups of kittens allocated to either an LTC or control group. The LTC were administered into both nares and the oropharynx of the 12 LTC group kittens, and all 19 kittens were inoculated with FHV-1 24 hours later. Clinical scores were determined daily for 28 days, and oropharyngeal mucosal materials were collected every 7 days to assess FHV-1 DNA quantities for comparison between groups. Conjunctivitis was more common in kittens in the control group on Days 15-28 (P = .01) and Days 1-28 (P = .02). Total respiratory scores were higher in the LTC group on days 15-28 (P = .03). The LTC group had significantly decreased FHV-1 DNA on swabs when compared to the control group on some postinoculation days, using 2 methods of calculation. Administration of LTC to kittens was shown to decrease FHV-1 DNA and some manifestations of illness in kittens when administrated 24 hours before inoculation, suggesting clinical benefit.
Sections du résumé
BACKGROUND
BACKGROUND
Feline herpesvirus-1 (FHV-1) infection can result in serious morbidity and mortality, especially in kittens. Immunotherapy using liposome-toll-like receptor (TLR) ligand complexes (LTC) has been shown to activate innate immune responses.
OBJECTIVES
OBJECTIVE
To determine in kittens whether mucosal administration of LTC before FHV-1 inoculation would decrease severity of clinical signs and decrease quantities of FHV-1 DNA in materials collected on oropharyngeal swabs.
ANIMALS
METHODS
Nineteen, 14-week-old, purpose-bred kittens.
METHODS
METHODS
Pilot clinical trial with 2 groups of kittens allocated to either an LTC or control group. The LTC were administered into both nares and the oropharynx of the 12 LTC group kittens, and all 19 kittens were inoculated with FHV-1 24 hours later. Clinical scores were determined daily for 28 days, and oropharyngeal mucosal materials were collected every 7 days to assess FHV-1 DNA quantities for comparison between groups.
RESULTS
RESULTS
Conjunctivitis was more common in kittens in the control group on Days 15-28 (P = .01) and Days 1-28 (P = .02). Total respiratory scores were higher in the LTC group on days 15-28 (P = .03). The LTC group had significantly decreased FHV-1 DNA on swabs when compared to the control group on some postinoculation days, using 2 methods of calculation.
CONCLUSIONS AND CLINICAL IMPORTANCE
CONCLUSIONS
Administration of LTC to kittens was shown to decrease FHV-1 DNA and some manifestations of illness in kittens when administrated 24 hours before inoculation, suggesting clinical benefit.
Identifiants
pubmed: 30847973
doi: 10.1111/jvim.15427
pmc: PMC6430869
doi:
Substances chimiques
DNA, Viral
0
Liposomes
0
Toll-Like Receptors
0
Types de publication
Clinical Trial, Veterinary
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
831-837Subventions
Organisme : Colorado Office of Economic Development and International Trade
Informations de copyright
© 2019 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
Références
Vaccine. 2009 Jul 16;27(33):4424-33
pubmed: 19490961
J Feline Med Surg. 2017 Aug;19(8):824-830
pubmed: 27432436
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
BMC Mol Biol. 2009 Dec 11;10:106
pubmed: 20003366
J Immunol. 1999 Aug 1;163(3):1552-61
pubmed: 10415059
Antiviral Res. 2006 Mar;69(3):165-72
pubmed: 16430975
Antiviral Res. 2010 Aug;87(2):195-203
pubmed: 20452378
J Clin Microbiol. 2003 Jun;41(6):2734-6
pubmed: 12791917
Infect Immun. 2009 Apr;77(4):1579-88
pubmed: 19179415
J Feline Med Surg. 2009 Oct;11(10):816-25
pubmed: 19782625
J Vet Intern Med. 2019 Mar;33(2):838-845
pubmed: 30770582
Am J Vet Res. 2008 Feb;69(2):289-93
pubmed: 18241028
J Feline Med Surg. 2013 Sep;15(9):785-808
pubmed: 23966005
J Feline Med Surg. 2011 May;13(5):333-46
pubmed: 21515221
J Vet Intern Med. 2017 Mar;31(2):279-294
pubmed: 28185306
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3516-21
pubmed: 14993594
J Feline Med Surg. 2006 Dec;8(6):400-11
pubmed: 16857403
J Vet Intern Med. 2012 Sep-Oct;26(5):1121-5
pubmed: 22860699
Vet J. 2014 Aug;201(2):202-6
pubmed: 24873978
J Feline Med Surg. 2015 Apr;17(4):353-8
pubmed: 25204453
J Comp Pathol. 1979 Apr;89(2):179-91
pubmed: 222816
J Vet Intern Med. 2018 Jan;32(1):406-417
pubmed: 29219213
Am J Vet Res. 2007 Jun;68(6):643-8
pubmed: 17542698
J Feline Med Surg. 2006 Jun;8(3):158-63
pubmed: 16442823
J Feline Med Surg. 2008 Dec;10(6):551-7
pubmed: 18539065
J Am Vet Med Assoc. 2014 May 1;244(9):1075-80
pubmed: 24739118
Nat Rev Immunol. 2004 Jul;4(7):499-511
pubmed: 15229469
J Am Assoc Lab Anim Sci. 2009 Jul;48(4):402-4
pubmed: 19653950
Antiviral Res. 2009 Jan;81(1):37-46
pubmed: 18840471
Nat Med. 2007 May;13(5):552-9
pubmed: 17479101
Expert Opin Drug Deliv. 2008 Jan;5(1):11-24
pubmed: 18095926
Science. 2007 Sep 14;317(5844):1522-7
pubmed: 17872438
J Vet Intern Med. 2019 Mar;33(2):831-837
pubmed: 30847973
Expert Rev Vaccines. 2010 Feb;9(2):157-73
pubmed: 20109027